QuiaPEG

Technology

 
PEGylation
Limitations on today's technology
QuiaPEG's advantages
R&D

Research & Development 

The Company is initially developing novel long-acting biopharmaceuticals for the treatment of metabolic disorders using the Company´s proprietary technology platform. The Company´s lead project is intended to reduce the burden of frequent injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes.
Contact
QuiaPEG Pharmaceuticals Holding AB

Visiting address

Karolinska Institutet Science Park
Fogdevreten 2
171 65 Solna
+46 (0) 70 693 12 53
info@quiapeg.com

Postal adress

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46-70-693 1253
Send a message